R&D Trends

ArQule, NIH collaborate to develop ARQ 092 in Proteus syndrome

Friday, November 14, 2014 10:39 AM

ArQule, a Woburn, Mass.-based biotech company engaged in the R&D of next-generation, small-molecule cancer therapeutics, has formed an agreement with the National Human Genome Research Institute (NHGRI) of the NIH, providing for the clinical development of ARQ 092, an orally available, selective small molecule inhibitor of AKT, in Proteus syndrome, a rare disease characterized by overgrowth of the skeleton, skin, adipose tissue and central nervous system.

More... »


Qiagen inks ninth master collaboration agreement for companion diagnostics

Wednesday, November 12, 2014 03:26 PM

Qiagen, a Netherlands-based holding company, has entered into a master collaboration agreement with the Swiss pharmaceutical company Novartis to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline.

More... »

CenterWatch

Idera Pharmaceuticals, Parent Project Muscular Dystrophy collaborate

Monday, November 10, 2014 12:20 PM

Idera Pharmaceuticals, a Cambridge, Mass.-based clinical-stage biopharmaceutical company, and nonprofit organization Parent Project Muscular Dystrophy (PPMD), based in Hackensack, N.J., are collaborating to advance Idera's proprietary Toll-like receptor (TLR) technology for the treatment of Duchenne muscular dystrophy.

More... »

Felicitex Therapeutics, Selvita collaborate to target cancer quiescence

Monday, November 10, 2014 12:18 PM

Cambridge, Mass.-based Felicitex Therapeutics, a privately owned drug discovery company, and Selvita, a Polish biotechnology company, have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors.

More... »

Study: CNS drugs have lower regulatory success rate, take longer to develop

Monday, November 10, 2014 12:02 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Developing drugs to treat a wide array of central nervous systems disorders—including depression, psychosis, epilepsy and Alzheimer’s disease—takes longer and has an overall success rate of less than half that of other types of drug candidates.

More... »

BIND Therapeutics inks oncology agreement with Merck

Friday, November 7, 2014 01:25 PM

BIND Therapeutics, a Cambridge, Mass.-based clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has signed an R&D agreement with Merck, through a subsidiary, to discover and develop novel nanomedicines for oncology. This collaboration will leverage BIND's proprietary nanomedicine technology to create targeted Accurins based on novel, potent payloads from Merck's preclinical oncology portfolio.

More... »

Bill & Melinda Gates Foundation awards PATH $156M for malaria research

Friday, November 7, 2014 01:23 PM

The Bill & Melinda Gates Foundation, of Seattle, Wash., has awarded $156 million to PATH, a Seattle-based international nonprofit organization, to support the PATH Malaria Vaccine Initiative (MVI) in building new vaccines that will interrupt the cycle of malaria parasite transmission and help realize the "accelerating to zero" agenda. Such vaccines would ensure parasite reintroduction is prevented by providing what could be called an "immunological bed net."

More... »

Study: Medication nonadherence a barrier to long-term health and public safety

Friday, November 7, 2014 01:22 PM

One out of four samples collected from patients with serious mental illness (SMI) did not contain the prescribed antipsychotic medication, according to clinical research from Ameritox's Ingenuity Health, a Baltimore, Md.-based provider of monitoring solutions to behavioral health clinicians. Coupled with nearly 40% of samples testing positive for illicit drugs or non-prescribed medications, the study illustrates the pervasiveness of medication nonadherence among those with SMI and highlights the potential barriers to long-term health and public safety.

More... »

EFPIA, Innovative Medicines Initiative form $348.2M Ebola+ program

Friday, November 7, 2014 01:19 PM

European Federation of Pharmaceutical Industries and Associations (EFPIA), a representative of the pharmaceutical industry operating in Europe, its specialized group Vaccines Europe and the Innovative Medicines Initiative have launched a $348.2 million call for proposals for an Innovative Medicines Initiative (IMI) program aimed to address the current Ebola crisis. The Ebola+ program will bring together the pharma industry and researchers in a collaborative program aimed to cover the current outbreak, as well as future needs in the space of hemorrhagic fevers.

More... »

Study: Large enterprises view business transformation as essential

Thursday, November 6, 2014 12:41 PM

Continual business transformation is crucial for companies to stay ahead of emerging players and maintain a competitive edge. From bringing new offerings to market to deploying IT systems to major capital expenditures, business transformation can take countless forms. Many large institutions, however, are struggling with their transformation efforts, according to a study from Oracle, a multinational computer technology corporation headquartered in Redwood City, Calif., and Forbes.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs